Sign In
Buy LYEL
$12.57
-2.32 (-15.58%)
At Close: Jun 03, 2026
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progress Presentations to highlight ne
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform
08:00am, Monday, 11'th Sep 2023
SOUTH SAN FRANCISCO. Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therap
Lyell Immunopharma to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 31'st Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data
09:29am, Saturday, 26'th Aug 2023
Lyell is a developer of personalized T-cell therapies for solid tumors, with two programs targeting various types of solid tumors. Their pipeline includes LYL797, a CART cell targeting TNBC and NSCLC,
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
04:05pm, Tuesday, 08'th Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
3 Red Hot Penny Stocks To Watch Before Next Week, Time To Buy?
11:41pm, Wednesday, 14'th Jun 2023
It was another wild ride in the stock market today. Whether you were trading penny stocks or Tesla, the thing weighing on everyone's conscience was the outcome of the June Fed meeting.
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
04:05pm, Wednesday, 07'th Jun 2023
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies f
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
08:30pm, Thursday, 04'th May 2023
Lyell Immunopharma (LYEL) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.28 per share a year ago.
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates
09:50pm, Tuesday, 28'th Feb 2023
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc
Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:17am, Friday, 09'th Dec 2022
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
11:18am, Friday, 04'th Nov 2022
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies fo
Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 91%: Here's is How to Trade
11:17am, Monday, 12'th Sep 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 91% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, t
Biotech ETF Tops in June: 5 Stocks That Outperform
02:52pm, Thursday, 30'th Jun 2022
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bar
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference
04:05pm, Tuesday, 07'th Jun 2022
SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies f
